Ongoing phase 3 trials of doublets and triplets in treatment-naive CLL
| Trial name/ID . | Patient population . | Therapies investigated . | Other information . |
|---|---|---|---|
| CELESTIAL-TNCLL NCT06073821 | Treatment-naive | Zanubrutinib plus sonrotoclax vs venetoclax plus obinutuzumab | 1-year fixed duration in both arms |
| MAJIC NCT05057494 | Treatment-naive | Acalabrutinib plus venetoclax vs venetoclax plus obinutuzumab | Both arms are MRD guided with a maximum of 2 years treatment |
| AMPLIFY NCT03836261 | Treatment-naive without del(17p) | Acalabrutinib plus venetoclax plus obinutuzumab or acalabrutinib plus venetoclax vs chemoimmunotherapy | Both acalabrutinib arms are 1-year fixed duration |
| CLL16 NCT05197192 | High-risk treatment-naive (del17p, TP53 mutated, or complex karyotype) | Acalabrutinib plus venetoclax plus obinutuzumab vs venetoclax plus obinutuzumab | Acalabrutinib for 24 cycles, venetoclax for 12 cycles in AVO arm |
| EA9161 NCT03701282 | Treatment-naive under age 70 years without del17p | Ibrutinib plus venetoclax plus obinutuzumab vs ibrutinib plus obinutuzumab | IVO is 18 months fixed duration for all patients |
| CLL17 NCT04608318 | Treatment-naive | Ibrutinib vs venetoclax plus obinutuzumab vs ibrutinib plus venetoclax | 1-year fixed duration in both venetoclax-containing arms |
| Trial name/ID . | Patient population . | Therapies investigated . | Other information . |
|---|---|---|---|
| CELESTIAL-TNCLL NCT06073821 | Treatment-naive | Zanubrutinib plus sonrotoclax vs venetoclax plus obinutuzumab | 1-year fixed duration in both arms |
| MAJIC NCT05057494 | Treatment-naive | Acalabrutinib plus venetoclax vs venetoclax plus obinutuzumab | Both arms are MRD guided with a maximum of 2 years treatment |
| AMPLIFY NCT03836261 | Treatment-naive without del(17p) | Acalabrutinib plus venetoclax plus obinutuzumab or acalabrutinib plus venetoclax vs chemoimmunotherapy | Both acalabrutinib arms are 1-year fixed duration |
| CLL16 NCT05197192 | High-risk treatment-naive (del17p, TP53 mutated, or complex karyotype) | Acalabrutinib plus venetoclax plus obinutuzumab vs venetoclax plus obinutuzumab | Acalabrutinib for 24 cycles, venetoclax for 12 cycles in AVO arm |
| EA9161 NCT03701282 | Treatment-naive under age 70 years without del17p | Ibrutinib plus venetoclax plus obinutuzumab vs ibrutinib plus obinutuzumab | IVO is 18 months fixed duration for all patients |
| CLL17 NCT04608318 | Treatment-naive | Ibrutinib vs venetoclax plus obinutuzumab vs ibrutinib plus venetoclax | 1-year fixed duration in both venetoclax-containing arms |